To summarise the practical experience with different timing of intervention and combination regimens for immunotherapy in advanced endometrial cancer, with a view to exploring the standard of care in immunotherapy and guiding clinical practice to obtain survival benefit.

The medical records of patients with primary and recurrent stage Ⅲ-Ⅳ (FIGO staging criteria) endometrial cancer admitted to the Department of Gynaecology of the First Medical Center of the General Hospital of the People's Liberation Army (PLA) and treated with a PD-1 inhibitor prior to surgery from June 2020 to December 2022 were retrospectively collected to evaluate the efficacy and safety of immunotherapy.

In terms of efficacy evaluation, among the 10 patients who were treated with immunotherapy at different times, 2 (20%) achieved complete response, 5 (50%) achieved partial response, 1 (10%) had stable disease, and 2 (20%) had progressive disease, with an overall objective response rate of 70%. Regarding safety, immunotherapy-related adverse reactions occurred in 2 cases, of which 1 was grade 2 and relieved by symptomatic treatment, and 1 was grade 3 and resulted in permanent discontinuation of the immunocheckpoint inhibitor. The overall safety was manageable and there were no immunotherapy-related deaths.

Immunotherapy for advanced endometrial cancer, either primary or recurrent, promotes tumour remission and prolongs progression-free survival, with an acceptable safey profile.